Manufacturers: Eli Lilly
Muvalaplin (LY3473329) is an orally administered small molecule developed by Eli Lilly that inhibits the formation of lipoprotein(a) (Lp(a)) by blocking the apo(a)-apo B100 interaction. It is under clinical investigation in adult participants with elevated Lp(a) at high risk for cardiovascular disease.
Muvalaplin (LY3473329) is an orally administered small molecule developed by Eli Lilly that inhibits the formation of lipoprotein(a) (Lp(a)) by blocking the apo(a)-apo B100 interaction. It is under clinical investigation in adult participants with elevated Lp(a) at high risk for cardiovascular disease.
Lp(a) formation inhibitor. Muvalaplin is an orally administered small molecule that inhibits the formation of lipoprotein(a) [Lp(a)] by blocking the apo(a)-apo B100 interaction.
3 associated conditions
